Stock Analysis

Insider Favorites Nanjing Vazyme Biotech And 2 Other Growth Leaders

SHSE:688105
Source: Shutterstock

As global markets continue to reach new heights, with major indices like the Dow Jones Industrial Average and S&P 500 hitting record intraday highs, investors are closely monitoring economic indicators and geopolitical developments. Amidst this backdrop of robust market activity and policy shifts, growth companies with high insider ownership often attract attention due to their potential for aligning management interests with shareholder value. In this environment, stocks that demonstrate strong growth potential while maintaining significant insider investment can be particularly appealing to investors seeking stability alongside opportunity.

Top 10 Growth Companies With High Insider Ownership

NameInsider OwnershipEarnings Growth
SKS Technologies Group (ASX:SKS)32.4%24.8%
Propel Holdings (TSX:PRL)36.9%37.6%
On Holding (NYSE:ONON)19.1%29.4%
Pharma Mar (BME:PHM)11.8%56.2%
CD Projekt (WSE:CDR)29.7%28.6%
Elliptic Laboratories (OB:ELABS)26.8%111.4%
EHang Holdings (NasdaqGM:EH)32.8%81.5%
Credo Technology Group Holding (NasdaqGS:CRDO)13.6%65.9%
Alkami Technology (NasdaqGS:ALKT)10.8%98.6%
Brightstar Resources (ASX:BTR)16.2%84.6%

Click here to see the full list of 1507 stocks from our Fast Growing Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Nanjing Vazyme Biotech (SHSE:688105)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Nanjing Vazyme Biotech Co., Ltd provides technology solutions in life science, biomedicine, and in vitro diagnostics, with a market cap of approximately CN¥9.75 billion.

Operations: Nanjing Vazyme Biotech Co., Ltd generates revenue through its technology solutions in the fields of life science, biomedicine, and in vitro diagnostics.

Insider Ownership: 12.9%

Earnings Growth Forecast: 90% p.a.

Nanjing Vazyme Biotech is experiencing robust growth, with revenue projected to increase by 23.7% annually, outpacing the Chinese market's average. The company's earnings are expected to grow significantly at 90% per year, having turned profitable this year with a net income of CNY 18.16 million compared to a loss previously. Despite high share price volatility and low future return on equity forecasts, insider ownership remains stable without substantial recent trading activity.

SHSE:688105 Earnings and Revenue Growth as at Dec 2024
SHSE:688105 Earnings and Revenue Growth as at Dec 2024

Changchun BCHT Biotechnology (SHSE:688276)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Changchun BCHT Biotechnology Co. Ltd. is a biopharmaceutical company involved in the research, development, production, and sale of human vaccines in China and internationally, with a market cap of CN¥11.09 billion.

Operations: The company generates its revenue from the biotechnology segment, amounting to CN¥1.61 billion.

Insider Ownership: 31.9%

Earnings Growth Forecast: 39.3% p.a.

Changchun BCHT Biotechnology is positioned for substantial growth, with revenue expected to rise 26.9% annually, surpassing the Chinese market's average. Earnings are forecast to grow significantly at 39.31% per year, despite recent declines in net income and sales compared to last year. The company's price-to-earnings ratio of 27.5x suggests it is undervalued relative to the market average of 36.6x, while insider ownership remains stable without significant recent trading activity.

SHSE:688276 Ownership Breakdown as at Dec 2024
SHSE:688276 Ownership Breakdown as at Dec 2024

King Slide Works (TWSE:2059)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: King Slide Works Co., Ltd. operates in Taiwan, focusing on the research, development, design, and sale of rail kits for servers and network communication equipment, with a market cap of NT$151.99 billion.

Operations: The company's revenue segments include NT$2.16 billion from Chuanhu Company and NT$7.12 billion from Chuan Yi Company.

Insider Ownership: 14.3%

Earnings Growth Forecast: 14.5% p.a.

King Slide Works has shown impressive financial performance, with earnings growing by 61.3% over the past year and revenue forecasted to grow at 20.4% annually, outpacing the Taiwanese market average. Despite high volatility in share price recently, the company maintains a strong return on equity forecast of 26.7%. Although there is no substantial insider trading activity reported in recent months, King Slide Works' growth trajectory remains robust with significant revenue expansion expected.

TWSE:2059 Ownership Breakdown as at Dec 2024
TWSE:2059 Ownership Breakdown as at Dec 2024

Summing It All Up

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're here to simplify it.

Discover if Nanjing Vazyme Biotech might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com